# Market Announcement

17 September 2026

## Nyrada Inc (ASX: NYR) – Trading Halt

Trading in the securities of Nyrada Inc ('NYR') will be halted at the request of NYR, pending the release of an announcement by NYR.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Monday, 21 September 2026; or
- the release of the announcement to the market.

NYR's request for a trading halt is attached below for the information of the market.

**Issued by**

ASX Compliance

17 September 2026 Sydney, Australia

# Trading Halt Request

---

ASX Limited
Listings Compliance, Sydney
Exchange Place
Level 27
39 Martin Place
Sydney NSW 2000

By Email Only: tradinghaltssydney@asx.com.au

Dear Manager

Nyrada Inc [ASX:NYR] (**Company or Nyrada**) hereby requests a trading halt in relation to the Company's Chess Depositary Interests (CDIs) quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding a material Capital Raising (**the Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist Nyrada in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.

- Nyrada requests that the trading halt remain in place until the earlier of commencement of normal trading on Monday, 21 September 2026, or when the announcement regarding the stated Purpose is released to the market.

- Nyrada is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

For and on behalf of the Board,

Yours faithfully,
David Franks
Company Secretary

## About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

*Authorised by John Moore, Non-Executive Chair, on behalf of the Board.*


**Investor & Media Enquiries:**

Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

**Company Secretary:**

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au


## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "plan," "should," "target," "will" or "would" or the negative of such terms or other similar expressions. Preclinical results may not translate to humans. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.